Beating animal heart created: University of Minnesota signs global license agreement with Miromatrix Medical

NewsGuard 100/100 Score

Taylor's research team created a beating animal heart in a laboratory

A major step in commercializing the groundbreaking research of Dr. Doris Taylor was achieved recently when the University of Minnesota signed an exclusive, global license agreement with Miromatrix Medical Inc. Dr. Taylor's research garnered worldwide attention in 2008 when her team announced that it had created a beating animal heart in her laboratory.

The technology licensed to Miromatrix holds the promise of one day enabling the replacement of entire human organs with non-transplantable organs, harvested from either animals or donors, which are stripped of their cells and recellularized with cells from the recipient or compatible donor cells.

"This is a major step forward for our technology commercialization efforts," said Tim Mulcahy, the University's vice president for research. "We took a methodical approach to this start-up and licensing agreement due to the tremendous potential of Dr. Taylor's research which, we believe, holds the potential to launch an entirely new industry on the scale of the medical device industry."

The agreement, negotiated by the university's Office for Technology Commercialization, includes equity for the university as well as future royalty and sublicensing fees.

"Miromatrix intends to commercialize a series of products based upon Dr. Taylor's platform as efficiently as possible, utilizing our own internal development as well as external collaborations," said CEO Robert Cohen. "Dr. Taylor's close involvement with the company will be tremendously beneficial as we ramp up this development effort."

Cohen joined Miromatrix as CEO in mid-November 2009. He was vice president of business and technology development at St. Jude Medical, and a former CEO of Travanti Pharma Inc. and Advanced Circulatory Systems, Inc., after holding top positions with the Pfizer Hospital Products Group and Sulzer Medica. Once Cohen joined the company, he and the University worked quickly to iron out the business and legal terms in the license agreement.

According to Cohen, Miromatrix expects to complete its initial round of financing in the next few months.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research identifies a unique protein fingerprint linked to very short sleep and increased diabetes risk